TY  - JOUR
A1  - Vallo, Stefan
A1  - Michaelis, Martin
A1  - Rothweiler, Florian
A1  - Bartsch, Georg
A1  - Gust, Kilian
A1  - Limbart, Dominik M.
A1  - Rödel, Franz
A1  - Wezel, Felix
A1  - Haferkamp, Axel
A1  - Cinatl, Jindrich
T1  - Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics
T2  - Translational oncology
N2  - Combination chemotherapy with gemcitabine and cisplatin in patients with metastatic urothelial cancer of the bladder frequently results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance could help to identify candidate treatments for an efficient second-line therapy. Six cisplatin- and six gemcitabine-resistant cell lines were established. Cell viability assays were performed to evaluate the sensitivity to 16 different chemotherapeutic substances. The activity of the drug transporter ATP-binding cassette transporter, subfamily B, member 1 (ABCB1, a critical mediator of multidrug resistance in cancer) was evaluated using fluorescent ABCB1 substrates. For functional assessment, cells overexpressing ABCB1 were generated by transduction with a lentiviral vector encoding for ABCB1, while zosuquidar was used for selective inhibition. In this study, 8 of 12 gemcitabine- or cisplatin-resistant cell lines were cross-resistant to carboplatin, 5 to pemetrexed, 4 to methotrexate, 3 to oxaliplatin, 5-fluorouracil, and paclitaxel, and 2 to cabazitaxel, larotaxel, docetaxel, topotecan, doxorubicin, and mitomycin c, and 1 of 12 cell lines was cross-resistant to vinflunine and vinblastine. In one cell line with acquired resistance to gemcitabine (TCC-SUPrGEMCI20), cross-resistance seemed to be mediated by ABCB1 expression. Our model identified the vinca alkaloids vinblastine and vinflunine, in Europe an already approved second-line therapeutic for metastatic bladder cancer, as the most effective compounds in urothelial cancer cells with acquired resistance to gemcitabine or cisplatin. These results demonstrate that this in vitro model can reproduce clinically relevant results and may be suitable to identify novel substances for the treatment of metastatic bladder cancer.
Y1  - 2015
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/75953
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-759532
SN  - 1936-5233
VL  - 8
IS  - 3
SP  - 210
EP  - 216
PB  - Elsevier
CY  - Amsterdam
ER  -